Lunatus Marketing and Consulting, a leading Middle East based firm focused on linking international health care companies with the region’s healthcare professionals, has announced the launch of ‘Cefaly,’ the first FDA-approved anti-migraine device for the treatment and prevention of migraine, during a press conference held today January 21st, 2016 at the Oberoi Hotel, Business Bay, Dubai. Present during the launch were Dr Lina Kouatly, Managing Director of Lunatus, Raphaël Ravet, Sales Manager at CEFALY Technology and Dr Wissam Barada, Specialist Neurologist at the American Center.
Recent medical reports have shown that millions of people worldwide suffer from migraines, which is characterized by intense pulsing or throbbing pain in one area of the head, accompanied by nausea or vomiting and sensitivity to light and sound. The National Institutes of Health has stressed that these debilitating headaches affect approximately 10 per cent of people worldwide and are three times more common in women than men. Looking to address this condition, 'Cefaly' works by introducing safe electric impulses that act on the nerves that transmit migraine pain, known as the trigeminal nerve.
“We are excited with the launch of ‘Cefaly,’ which is expected to help reduce cases of migraine attacks,” said Dr Lina Kouatly, Managing Director, Lunatus. “There have been a lot of reported cases of people suffering from migraines. With this new device, ‘Cefaly’ offers an effective, ideal and drug-free remedy that is not only aimed at treating the condition but also helps reduce these attacks.”
“The launch of this new breakthrough device proves to be both timely and strategic. ‘Cefaly’ has been proven to be effective & safe based on several clinical studies. Lunatus is proud to be the first company to make this new device available — bringing an effective solution to migraine sufferers. We encourage those who suffer from periodic migraine attacks to join the tens of thousands of people around the world who have tried 'Cefaly' and are now free of migraine pain and pain relieving medications,” concluded Kouatly, Managing Director, Lunatus.